PRO 140 in Treatment-Experienced HIV-1 Subjects

HIV-1-infection Clinical Trial

Official title:

A Multi-center, Two-Part, Single-Arm, Open Label, 25-Week Trial With PRO 140 in Treatment-Experienced HIV-1 Subjects

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03902522
• Other study ID #: PRO 140_CD02_OpenLabel
• Status: Active, not recruiting
• Phase: Phase 2/Phase 3
• Start date: June 25, 2018
• Est. completion date: August 30, 2022

Study information

• Verified date: September 2021
• Source: CytoDyn, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objectives of the trial are to assess the efficacy, clinical safety and tolerability parameters of PRO 140 in combination with failing ART during the initial one-week treatment period, and in combination with Optimized Background Therapy during the subsequent 24-week treatment period.

Description:

PRO 140, in combination with other antiretroviral agents, is indicated for treatment experienced adult HIV-1 patients infected with CCR5-tropic virus. These patients must demonstrate evidence of HIV-1 replication despite ongoing antiretroviral therapy and have documented genotypic or phenotypic resistance to at least one ART drug within three drug classes (or within two or more drug classes with limited treatment option). The options may be limited as a result of drug antiviral class cross-resistance, documented treatment intolerance, documented objective assessments such as renal or hepatic insufficiency (e.g. high creatinine at baseline, limiting treatment options due to potential for toxicity), past adverse reactions such as hypersensitivity reactions or neuropsychiatric issues that could limit use of currently approved drugs. Study population includes treatment-experienced HIV-infected patients with CCR5-tropic virus who demonstrates evidence of HIV-1 replication despite ongoing antiretroviral therapy with documented genotypic or phenotypic resistance to ART drugs within three drug classes (or within two drug classes with limited treatment option). The primary objectives of the trial are to assess the efficacy, clinical safety and tolerability parameters of PRO 140 in combination with failing ART during the initial one-week treatment period, and in combination with Optimized Background Therapy during the subsequent 24-week treatment period.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 25
• Est. completion date: August 30, 2022
• Est. primary completion date: July 30, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Males and females, age =18 years

2. Exclusive CCR5-tropic virus at Screening Visit as determined by Monogram Biosciences Trofile® Assay

3. Have a history of at least 3 months on current antiretroviral regimen

4. Treatment-experienced HIV-infected patients with documented genotypic or phenotypic resistance to at least one ART drug within three drug classes OR Treatment-experienced HIV-infected patients with documented genotypic or phenotypic resistance to at least one ART drug within two drug classes and have limited treatment option. The options may be limited as a result of drug antiviral class cross-resistance, documented treatment intolerance, documented objective assessments such as renal or hepatic insufficiency (e.g. high creatinine at baseline, limiting treatment options due to potential for toxicity), past adverse reactions such as hypersensitivity reactions or neuropsychiatric issues that could limit use of currently approved drugs.

5. Be willing to remain on treatment without any changes or additions to the OBT regimen, except for toxicity management or upon meeting criteria for treatment failure

6. Plasma HIV-1 RNA = 400 copies/mL at Screening Visit as determined by Human Immunodeficiency Virus 1 (HIV-1) Quantitative, RNA (Roche Taqman® Real-Time PCR) and documented detectable viral load (HIV-1 RNA >50 copies/ml) within the last 3 months prior to Screening Visit

7. Laboratory values at Screening of:

1. Absolute neutrophil count (ANC) =750/mm3

2. Hemoglobin (Hb) =10.5 gm/dL (male) or = 9.5 gm/dL (female)

3. Platelets =75,000 /mm3

4. Serum alanine transaminase (SGPT/ALT) <5 x upper limit of normal (ULN)

5. Serum aspartate transaminase (SGOT/AST) <5 x ULN

6. Bilirubin (total) <2.5 x ULN unless Gilbert's disease is present or subject is receiving atazanavir in the absence of other evidence of significant liver disease

7. Creatinine =1.5 x ULN

8. Clinically normal resting 12-lead ECG at Screening Visit or, if abnormal, considered not clinically significant by the Principal Investigator

9. Both male and female patients and their partners of childbearing potential must agree to use 2 medically accepted methods of contraception (e.g., barrier contraceptives [male condom, female condom, or diaphragm with a spermicidal gel], hormonal contraceptives [implants, injectables, combination oral contraceptives, transdermal patches, or contraceptive rings], and intrauterine devices) during the course of the study (excluding women who are not of childbearing potential and men who have been sterilized). Females of childbearing potential must have a negative serum pregnancy test at Screening visit and negative urine pregnancy test prior to receiving the first dose of study drug

10. Willing and able to participate in all aspects of the study, including use of SC medication, completion of subjective evaluations, attendance at scheduled clinic visits, and compliance with all protocol requirements as evidenced by providing written informed consent Note: Subjects diagnosed with either substance dependence or substance abuse or any history of a concomitant condition (e.g., medical, psychologic, or psychiatric) may be enrolled if in the opinion of site investigator these circumstances would not interfere with the subject's successful completion of the study requirements

Exclusion Criteria:

1. Documented CXCR4-tropic virus or Dual/Mixed tropic (R5X4) virus as determined by HIV-1 tropism assay

2. Patients with no viable treatment options ( i.e., no fully active antiretroviral drug available which can be effectively combined to form a viable new OBT)

3. Any active infection or malignancy requiring acute therapy (with the exception of local cutaneous Kaposi's sarcoma) Note: Subjects infected by the hepatitis B virus or hepatitis C virus will be eligible for the study if they have no signs of hepatic decompensation and meet the liver function tests eligibility criteria

4. Laboratory test values of = grade 3 DAIDS laboratory abnormality with the exception of the absolute CD4+ count criterion of <200/mm3

5. Females who are pregnant, lactating, or breastfeeding, or who plan to become pregnant during the study

6. Unexplained fever or clinically significant illness within 1 week prior to the first study dose

7. Any vaccination within 2 weeks prior to the first study dose

8. Subjects weighing < 35kg

9. History of anaphylaxis to oral or parenteral drugs

10. History of Bleeding Disorder or patients on anti-coagulant therapy

11. Participation in an experimental drug trial(s) within 30 days of the Screening Visit

12. Any known allergy or antibodies to the study drug or excipients

13. Treatment with any of the following:

1. Radiation or cytotoxic chemotherapy with 30 days prior to the screening visit

2. Immunosuppressants within 60 days prior to the screening visit

3. Immunomodulating agents (e.g., interleukins, interferons), hydroxyurea, or foscarnet within 60 days prior to the screening visit

4. Oral or parenteral corticosteroids within 30 days prior to the Screening Visit. Subjects on chronic steroid therapy >5 mg/day will be excluded with the following exception:

• Subjects on inhaled, nasal, or topical steroids will not be excluded

14. Any other clinical condition that, in the Investigator's judgment, would potentially compromise study compliance or the ability to evaluate safety/efficacy

Related Conditions & MeSH terms

• HIV-1-infection

Intervention

Drug:
• PRO 140
2 injections of PRO 140 (2 X 2 mL/inj.)

Locations

Country	Name	City	State
United States	CD02_OpenLabel Investigational Site	Bellaire	Texas
United States	CD02_OpenLabel Investigational Site	Chicago	Illinois
United States	CD02_OpenLabel Investigational Site	Decatur	Georgia
United States	CD02_OpenLabel Investigational Site	Fort Pierce	Florida
United States	CD02_OpenLabel Investigational Site	Houston	Texas
United States	CD02_OpenLabel Investigational Site	Houston	Texas
United States	CD02_OpenLabel Investigational Site	Miami	Florida
United States	CD02_OpenLabel Investigational Site	Miami	Florida
United States	CD02_OpenLabel Investigational Site	Miami	Florida
United States	CD02_OpenLabel Investigational Site	New Haven	Connecticut
United States	CD02_OpenLabel Investigational Site	Orlando	Florida
United States	CD02_OpenLabel Investigational Site	Palm Springs	California
United States	CD02_OpenLabel Investigational Site	San Francisco	California
United States	CD02_OpenLabel Investigational Site	Spokane	Washington
United States	CD02_OpenLabel Investigational Site	Syracuse	New York
United States	CD02_OpenLabel Investigational Site	West Palm Beach	Florida
United States	CD02_OpenLabel Investigational Site	Wichita	Kansas

Sponsors (1)

Lead Sponsor	Collaborator
CytoDyn, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of participants with = 0.5 log10 reduction in HIV-1 RNA viral load from baseline at the end of the initial 1-week treatment period		1-week
Secondary	Proportion of participants with = 1 log10 reduction in HIV-1 RNA viral load from baseline at the end of the initial 1-week treatment period		1-week
Secondary	Mean change from Baseline in HIV-1 RNA levels (log10 copies/mL) at the end of the initial 1-week treatment period		1-week
Secondary	Percentage of participants achieving HIV-1 RNA < 400 copies/mL at week 25		week 25
Secondary	Percentage of participants achieving HIV-1 RNA < 50 copies/mL at week 25		week 25
Secondary	Mean change from Baseline in HIV-1 RNA levels (log10 copies/mL)		week 25
Secondary	Mean change from Baseline in CD4 cell count at the end of the initial 1-week treatment period		1-week
Secondary	Mean change from Baseline in CD4 cell count at week 25		week 25